Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Mayr, Martina ^a   Becker, Karen ^a   Schulte, Nadine ^b   Belle, Sebastian ^b   Hofheinz, Ralf ^b   Krause, Annekatrin ^c   Schmid, Roland M ^a   Röcken, Christoph ^d   Ebert, Matthias P ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

Chemotherapy; Gastric cancer; Imatinib; PDGF

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; DEOXYCYTIDINE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PYRIMIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; FLUID RETENTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PAIN; PHASE 1 CLINICAL TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH PERFORATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; STOMACH NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CISPLATIN; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 84871483502     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-587     Document Type: Article

References (27)

1. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003, 14(2):31-36.
2. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8(2):163-168. 10.1023/A:1008243606668, 9426339.
3. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 3. CD004064..
4. Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008, 68(3):299-317. 10.2165/00003495-200868030-00004, 18257608.
5. Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 2009, 21(4):381-385. 10.1097/CCO.0b013e32832c42e0, 19412098.
6. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001, 411(6835):355-365. 10.1038/35077225, 11357143.
7. Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope 2006, 116(8):1409-1416. 10.1097/01.mlg.0000225895.40732.52, 16885745.
8. Sumida T, Kitadai Y, Shinagawa K, Tanaka M, Kodama M, Ohnishi M, Ohara E, Tanaka S, Yasui W, Chayama K. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. Int J Cancer 2011, 128(9):2050-2062. 10.1002/ijc.25812, 21387285.
9. Lindmark G, Sundberg C, Glimelius B, Pahlman L, Rubin K, Gerdin B. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 1993, 69(6):682-689.
10. Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, Ooi A. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. BMC Cancer 2010, 10(1):659. 10.1186/1471-2407-10-659, 3009982, 21118571.
11. Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 2004, 93(1):78-86. 10.1016/j.ygyno.2003.12.041, 15047217.
12. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 2006, 169(6):2054-2065. 10.2353/ajpath.2006.060653, 1762464, 17148668.
13. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001, 3(5):512-516. 10.1038/35074588, 11331881.
14. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4(11):839-849. 10.1038/nrc1477, 15516957.
15. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K, Heldin CH. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992, 7(4):261-266. 10.3109/08977199209046408, 1284870.
16. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004, 15(4):275-286. 10.1016/j.cytogfr.2004.03.002, 15207817.
17. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004, 31(2 Suppl 6):18-23.
18. Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, Tanaka M, Shinagawa K, Tanaka S, Yasui W, Chayama K. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor beta is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 2010, 101(9):1984-1989. 10.1111/j.1349-7006.2010.01639.x, 20624165.
19. Al-Batran SE, Atmaca A, Schleyer E, Pauligk C, Hosius C, Ehninger G, Jager E. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer-a dose-escalation Phase I tria. Cancer 2007, 109(9):1897-1904. 10.1002/cncr.22622, 17377918.
20. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24(18):2903-2909. 10.1200/JCO.2005.05.0245, 16782930.
21. Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol 2007, 37(1):30-37.
22. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002, 13(12):1893-1898. 10.1093/annonc/mdf323, 12453857.
23. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009, 20(9):1529-1534. 10.1093/annonc/mdp047, 19474114.
24. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71(3):587-591. 10.1038/bjc.1995.114, 2033628, 7533517.
25. Chiarugi M, Galatioto C, Lippolis PV, Seccia M. Multiple bowel perforations complicating imatinib treatment for advanced gastrointestinal stromal tumor. J Am Coll Surg 2008, 206(2):386-387. 10.1016/j.jamcollsurg.2007.04.048, 18222396.
26. Roviello F, Rossi S, Marrelli D, De Manzoni G, Pedrazzani C, Morgagni P, Corso G, Pinto E. Perforated gastric carcinoma: a report of 10 cases and review of the literature. World J Surg Oncol 2006, 4:19. 10.1186/1477-7819-4-19, 1524767, 16573818.
27. Wilke H, Korn M, Vanhofer U, Fink U, Stahl M, Preusser P, Kohne C, Klassen U, Harstrick A, Schmoll HJ, et al. Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother 1996, 6(3):123-126.